{
    "clinical_study": {
        "@rank": "92371", 
        "arm_group": [
            {
                "arm_group_label": "Octagam 5%", 
                "description": "Primary Immune Deficiency Syndrome patients receiving Octagam 5% by infusion who have been treated with a marketed IVIG product for at least 6 months."
            }, 
            {
                "arm_group_label": "Other marketed IVIG product", 
                "description": "Primary Immune Deficiency Syndrome patients receiving marketed IVIG product other than Octagam 5% by infusion as treatment for at least 6 months."
            }
        ], 
        "brief_summary": {
            "textblock": "Study Design:\n\n      This is a 2 arm non-interventional trial that will compare the occurrence of adverse drug\n      reactions between Octagam 5% and other marketed IVIG infusion treatments."
        }, 
        "brief_title": "Octagam 5% Versus Comparator Post Marketing Trial", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Immune Deficiency Disorder", 
        "condition_browse": {
            "mesh_term": "Immunologic Deficiency Syndromes"
        }, 
        "detailed_description": {
            "textblock": "This Post Marketing Study is a prospective, 2-armed, multicenter, non-interventional study.\n      Patients will either be administered the brand of IGIV therapy ordered by their prescribing\n      physician, or for patients issued unspecified or generic prescriptions of IGIV therapy,\n      octagam\u00ae 5% or another brand of IGIV therapy will be provided by the Investigator according\n      to federal, state and local regulations and good clinical practice (GCP) guidelines.\n\n      The primary objective is to assess and evaluate the safety profile of octagam\u00ae 5% during or\n      after administration under routine clinical use for all labeled indications, with a special\n      emphasis on the occurrence of TEEs. The incidence of TEEs in patients receiving octagam\u00ae 5%\n      will be compared with the incidence rate in a matching concurrent control group of patients\n      receiving other IGIVs for routine clinical use."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male and female patients aged 18 years.\n\n          2. Patients with confirmed diagnosis of Primary Humoral Immunodeficiency (PI) as stated\n             by the World Health Organization and requiring immunoglobulinreplacement therapy due\n             to hypogammaglobulinemia or agammaglobulinemia.\n\n          3. Patients on regular treatment (every 3 to 4 weeks) with low dose IGIV (1 g/kg) for a\n             period of at least 6 months without changing the brand.\n\n        Exclusion Criteria:\n\n          1. Patients with a history of TEEs within the previous 24 months.\n\n          2. Patients with a regular treatment frequency of more than once every 3 to 4 weeks."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients over 18 years old with Primary Immune Deficiency Syndrome PID receiving marketed\n        IVIG as treatment"
            }
        }, 
        "enrollment": {
            "#text": "2500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859754", 
            "org_study_id": "GAM5-28"
        }, 
        "intervention": [
            {
                "arm_group_label": "Octagam 5%", 
                "description": "Intravenous immunoglobulin 5%", 
                "intervention_name": "Octagam 5%", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Other marketed IVIG product", 
                "description": "Any intravenous immunoglobulin marketed product approved for the treatment of PID", 
                "intervention_name": "Other marketed IVIG product", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulins, Intravenous", 
                "Rho(D) Immune Globulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Primary Immune Deficiency Syndrome", 
            "Primary immunodeficiency Disease (PIDD)", 
            "PID"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "araceli@asthmadoc.com", 
                    "last_name": "Araceli Vasquez, MD", 
                    "phone": "818-366-8112", 
                    "phone_ext": "112"
                }, 
                "facility": {
                    "address": {
                        "city": "Granada Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91344"
                    }, 
                    "name": "Allergy and Asthma Relief Experts"
                }, 
                "investigator": {
                    "last_name": "Jacob Offenberger, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mclawges@uci.edu", 
                    "last_name": "Maritza Clawges", 
                    "phone": "949-824-2032"
                }, 
                "facility": {
                    "address": {
                        "city": "Irvine", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92697"
                    }, 
                    "name": "University of California Irvine"
                }, 
                "investigator": {
                    "last_name": "Sudhir Gupta, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "LUllate@immunoe.com", 
                    "last_name": "Laura Ullate"
                }, 
                "facility": {
                    "address": {
                        "city": "Centennial", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80112"
                    }, 
                    "name": "Immunoe Research"
                }, 
                "investigator": {
                    "last_name": "Isaac Melamed, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "midlandspeds@gmail.com", 
                    "last_name": "Ai Lan Kobayashi, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68124"
                    }, 
                    "name": "Asthma and Allergy Associates of Omaha"
                }, 
                "investigator": {
                    "last_name": "Roger Kobayashi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "georgenicholas26@aol.com", 
                    "last_name": "George Calcances, RN", 
                    "phone": "631-751-3000"
                }, 
                "facility": {
                    "address": {
                        "city": "East Setauket", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11733"
                    }, 
                    "name": "North Shore Hematology Oncology Associates"
                }, 
                "investigator": {
                    "last_name": "Jeffrey Vacirca, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ann@optimed.us.com", 
                    "last_name": "Ann Urbank, NP", 
                    "phone": "614-430-8022", 
                    "phone_ext": "109"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43235"
                    }, 
                    "name": "Optimed Research Ltd"
                }, 
                "investigator": {
                    "last_name": "Donald McNeil, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "coral_expressions@yahoo.com", 
                    "last_name": "Patricia Bak", 
                    "phone": "419-843-8815"
                }, 
                "facility": {
                    "address": {
                        "city": "Toledo", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43617"
                    }, 
                    "name": "The Toledo Institute of Clinical Research, Inc."
                }, 
                "investigator": {
                    "last_name": "Syed Rehman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "patti_wingate@mhri.org", 
                    "last_name": "Patti Wingate", 
                    "phone": "401-729-2225"
                }, 
                "facility": {
                    "address": {
                        "city": "Pawtucket", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02860"
                    }, 
                    "name": "Memorial Hospital of Rhode Island"
                }, 
                "investigator": {
                    "last_name": "Iole Ribizzi-Akhtar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jgomillion@breatheamerica.com", 
                    "last_name": "John Gomillion", 
                    "phone": "615-665-7130"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "BreatheAmerica, Inc."
                }, 
                "investigator": {
                    "last_name": "David Hagaman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jtucker@aararesearch.com", 
                    "last_name": "Julie Tucker", 
                    "phone": "214-365-0365"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }, 
                    "name": "AARA Research Center"
                }, 
                "investigator": {
                    "last_name": "William Lumry, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam\u00ae Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events", 
        "overall_official": {
            "affiliation": "International Medical Monitor, Octapharma AG", 
            "last_name": "Wolfgang Frenzel", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence Rate of Thromboembolytic events", 
            "safety_issue": "Yes", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859754"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Octapharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Octapharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}